Victory Capital Management
BCRX icon

Victory Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Victory Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$845K Buy
84,506
+58,150
+221% +$526K ﹤0.01% 1953
2026
Q1 		$251K Sell
26,356
-298,695
-92% -$2.32M ﹤0.01% 2157
2025
Q4 		$2.54M Buy
325,051
+265,564
+446% +$1.92M ﹤0.01% 1524
2025
Q3 		$452K Sell
59,487
-554
-0.9% -$4.61K ﹤0.01% 2054
2025
Q2 		$538K Buy
60,041
+36,256
+152% +$338K ﹤0.01% 2047
2025
Q1 		$178K Buy
23,785
+404
+2% +$3.26K ﹤0.01% 2241
2024
Q4 		$176K Sell
23,381
-1,468
-6% -$11.1K ﹤0.01% 2262
2024
Q3 		$189K Sell
24,849
-737
-3% -$5.6K ﹤0.01% 2237
2024
Q2 		$158K Sell
25,586
-558
-2% -$3.08K ﹤0.01% 2239
2024
Q1 		$133K Sell
26,144
-698
-3% -$3.92K ﹤0.01% 2265
2023
Q4 		$161K Buy
26,842
+6,434
+32% +$37.3K ﹤0.01% 2266
2023
Q3 		$144K Buy
20,408
+199
+1% +$1.43K ﹤0.01% 2254
2023
Q2 		$142K Sell
20,209
-469
-2% -$3.76K ﹤0.01% 2264
2023
Q1 		$172K Sell
20,678
-2,512,906
-99% -$24.2M ﹤0.01% 2277
2022
Q4 		$29.1M Sell
2,533,584
-986,647
-28% -$12.3M 0.03% 644
2022
Q3 		$44.4M Sell
3,520,231
-1,044,699
-23% -$13.4M 0.05% 503
2022
Q2 		$48.3M Buy
4,564,930
+1,011,409
+28% +$10.4M 0.06% 485
2022
Q1 		$57.5M Buy
3,553,521
+3,112,255
+705% +$49.9M 0.06% 462
2021
Q4 		$6.11M Sell
441,266
-22,908
-5% -$303K 0.01% 1278
2021
Q3 		$6.67M Sell
464,174
-189,655
-29% -$2.99M 0.01% 1238
2021
Q2 		$10.3M Sell
653,829
-31,655
-5% -$430K 0.01% 1115
2021
Q1 		$6.97M Sell
685,484
-241,195
-26% -$2.49M 0.01% 1238
2020
Q4 		$6.9M Sell
926,679
-270,876
-23% -$1.4M 0.01% 1164
2020
Q3 		$4.11M Buy
1,197,555
+907,591
+313% +$3.89M 0.01% 1236
2020
Q2 		$1.38M Buy
289,964
+265,145
+1,068% +$1.06M ﹤0.01% 1574
2020
Q1 		$50K Buy
+24,819
New +$68.3K ﹤0.01% 2518
2019
Q4 		– Sell
-17,281
Closed -$50K – 2700
2019
Q3 		$50K Buy
+17,281
New +$53.8K ﹤0.01% 2677

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Victory Capital Management's BCRX Position: Q2 2026 in Review

Victory Capital Management increased its BioCryst Pharmaceuticals (BCRX) stake by 221% in Q2 2026, buying an estimated $526K and bringing the position to 84,506 shares worth $845K. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

Victory Capital Management first reported a position in BCRX in Q3 2019 and has held it in 27 quarters since. The position peaked at $57.5M in Q1 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Victory Capital Management held 84,506 shares of BioCryst Pharmaceuticals worth $845K as of Q2 2026.
  • Victory Capital Management bought 58,150 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $526K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1953 holding.
  • Victory Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2019 and has held it in 27 quarters since.
  • Victory Capital Management's BioCryst Pharmaceuticals position peaked at $57.5M in Q1 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.